Last reviewed · How we verify

NCT05150470: DPOAM

Evaluation of the Dental Movements Caused by Oral Appliance in Sleep Apnea Syndrome

Completed NA Last updated 8 September 2025
What this trial tests

NA trial testing prevention in Sleep Apnea Syndromes in 180 participants. Completed in 25 December 2022.

Timeline
25 November 2021
Primary endpoint
25 November 2022
25 December 2022

Quick facts

Lead sponsorCentre Hospitalier de Valence
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment180
Start date25 November 2021
Primary completion25 November 2022
Estimated completion25 December 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier de Valence

Who can join

18 and older, any sex, with Sleep Apnea Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The DO OAM study is a mono-center, interventional, prospective study carried out in CH VALENCE. It will estimate the prevalence of dental movements in patients treated by oral Appliance for Sleep Apnea syndrome. The investigators will used fingerprinting technique by taking multiple photographs of the teeth that allow for the three-dimensional reconstruction of the teeth this study will provide a better understanding of dental movement caused by oral appliance

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Sleep Apnea Syndromes

Currently open trials in the same condition.

Other Centre Hospitalier de Valence trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05150470.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing